Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1056/NEJMc2000987 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Dengue virus IgG and neutralizing antibody titers measured with standard and mature viruses are protective.
Nat Commun
January 2025
Viral Epidemiology and Immunity Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
The standard dengue virus (DENV) neutralization assay inconsistently predicts dengue protection. We compare how IgG ELISA, envelope domain III (EDIII), or non-structural protein 1 (NS1) binding antibodies, and titers from plaque reduction neutralization tests (PRNTs) using standard and mature viruses are associated with dengue. The ELISA measures IgG antibodies that bind to inactivated DENV1-4.
View Article and Find Full Text PDFLocalized Inflammation in Dengue Vaccine-Induced Skin Rash Is Not Associated with Continuous Presence of Dengue Virus Genome.
J Invest Dermatol
December 2024
Department of Microbiology and Molecular Genetics, Larner College of Medicine, The University of Vermont, Burlington, Vermont, USA; Vaccine Testing Center, Larner College of Medicine, The University of Vermont, Burlington, Vermont, USA. Electronic address:
Vaccination with the tetravalent live-attenuated dengue virus (DENV) vaccines TV003 and TV005 causes a mild, relatively localized erythematous maculopapular skin rash in most dengue-naïve vaccinees. Human challenge model DENV strains, DENV2Δ30 and DENV3Δ30, trigger a confluent skin rash over most of the body in most unvaccinated participants. To determine the etiology of these rashes, we performed in situ hybridization for DENV genome and assessed cellular infiltration by H&E staining in skin biopsies from humans infected with live-attenuated dengue vaccine DENV2Δ30 or DENV3Δ30 challenge strains.
View Article and Find Full Text PDFA case report on symptomatic disease caused by serotype 4 vaccine virus following tetravalent anti-dengue vaccination.
Travel Med Infect Dis
October 2024
Faculdade de Medicina, Universidade Federal de Mato Grosso do Sul, Campo Grande, MS, Brazil; Fundação Oswaldo Cruz - Mato Grosso do Sul, Campo Grande, MS, Brazil; Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA. Electronic address:
[The dengue vaccine: a major scientific challenge and a public health issue].
Med Sci (Paris)
October 2024
Unité Immunité innée et virus, Institut Pasteur Paris France.
Almost half of the world's population is exposed to the risk of transmission of the four dengue virus serotypes (DENV 1-4), by mosquitoes of the genus Aedes. A dengue vaccine is effective if it induces prolonged protective immunity against all circulating viral strains, irrespective of the age and infection history of the vaccinated subject. An effective vaccine strategy against dengue is based on the injection of live attenuated viruses in a tetravalent formulation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!